SureTrader
Interactive Brokers Advertisement
SureTrader
Home > Boards > US Listed > Miscellaneous > Rigel Pharmaceuticals Inc. (RIGL)

7:40AM On The Wires (WIRES) :

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
surf1944 Member Profile
 
Followed By 418
Posts 22,593
Boards Moderated 3
Alias Born 09/11/06
160x600 placeholder
Rigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology As... "PR Newswire (US)" - 6/22/2017 4:05:00 PM
FDA Accepts Rigel's New Drug Application for TAVALISSE™ (fostamatinib disodium) for the Treatment of Chronic ITP "PR Newswire (US)" - 6/19/2017 7:30:00 AM
Breakfast Technical Briefing on Generic Drugs Stocks -- Innocoll, Rigel Pharma, Tetraphase Pharma, and Catalent "PR Newswire (US)" - 6/5/2017 6:10:00 AM
Rigel to Present at Jefferies 2017 Global Healthcare Conference "PR Newswire (US)" - 6/1/2017 7:30:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 5/30/2017 4:30:18 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/30/2017 4:18:11 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/12/2017 6:07:05 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/12/2017 6:03:45 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/12/2017 6:02:55 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/12/2017 6:01:06 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/12/2017 6:00:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/12/2017 5:00:40 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/2/2017 4:05:28 PM
Rigel Announces First Quarter 2017 Financial Results and Provides Company Update "PR Newswire (US)" - 5/2/2017 4:01:00 PM
Rigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States "PR Newswire (US)" - 4/27/2017 7:30:00 AM
Rigel Announces Conference Call and Webcast to Report First Quarter 2017 Financial Results "PR Newswire (US)" - 4/25/2017 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/21/2017 5:56:14 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/21/2017 5:51:45 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/21/2017 5:47:56 PM
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP "PR Newswire (US)" - 4/17/2017 4:05:00 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 3/29/2017 4:42:13 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 3/29/2017 4:35:36 PM
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 3/7/2017 5:26:39 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 3/7/2017 5:02:53 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/7/2017 4:14:12 PM
surf1944   Friday, 05/06/11 09:58:11 AM
Re: surf1944 post# 130
Post # of 424 
7:40AM On The Wires (WIRES) :

Rigel Pharmaceuticals, Inc. (RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer (PFE) is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D. Rigel is evaluating the details of R343's development to date and expects to design a Phase 2 clinical trial with R343 later this year.



surf's up......crikey



SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist